BioCentury | Dec 8, 2017
Company News

Astellas acquires build-to-buy Mitobridge

...held the option under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....
BioCentury | Dec 2, 2017
Company News

Astellas acquires build-to-buy Mitobridge

...million in milestones under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....
...The deal is expected to close in the next several weeks. Jaime De Leon MA-0211 MA-0217 MTB-1 MTB-2 Astellas Pharma Inc. Mitobridge Inc. Mitokyne Inc. MPM...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...basic research and creation of drug-like molecules,” he said. Mitobridge was created by MPM as Mitokyne Inc....
BioCentury | Aug 16, 2017
Clinical News

Mitobridge's DMD candidate MA-0211 enters Phase I

...expects to begin a trial in ambulatory DMD patients next year. In 2013, Mitobridge (formerly Mitokyne Inc....
BioCentury | May 28, 2015
Company News

Astellas adds muscle disease, ophthalmology TAs

...Astellas also said it would explore muscle diseases in partnership with Mitobridge Inc. (formerly Mitokyne...
BioCentury | May 18, 2015
Finance

New (Bio)ventures at MPM

...Astellas and MPM participated in a $45 million series A round for Mitobridge Inc. (then Mitokyne Inc....
BioCentury | Oct 18, 2014
Company News

Astellas, CoMentis end AD collaboration

...commercial milestones and royalties (see BioCentury, May 5, 2008) . In 2013, Astellas partnered with MitoKyne Inc....
BioCentury | May 19, 2014
Emerging Company Profile

Mitokyne: Energy pipeline

...mitochondrial activity to treat neuromuscular, cardiovascular and metabolic diseases, starting with Orphan or hereditary indications. Mitokyne...
...and former CEO of Epizyme Inc. Shiosaki is managing partner at MPM Capital, which seeded Mitokyne...
...$45 million series A round last October. Under a deal with Astellas Pharma Inc. , Mitokyne...
BioCentury | Mar 17, 2014
Emerging Company Profile

Partikula: Mitochondrial delivery

...delivering payloads into the mitochondria. Partikula is not the only company focused on mitochondria, however. Mitokyne Inc....
...neurodegenerative disorders as well as aging diseases. Details about Mitokyne's technology are undisclosed. Last year, Mitokyne...
...for up to $730 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Mitokyne Inc....
BioCentury | Oct 14, 2013
Company News

Mitokyne board of directors update

Mitokyne Inc. , Boston, Mass. Business: Neurology, Endocrine/Metabolic Appointed: Rich Aldrich, partner at Longwood Founders Fund; Ansbert Gadicke, managing director at MPM Capital; and an undisclosed representative from Astellas Pharma Inc. WIR Staff...
Items per page:
1 - 10 of 13
BioCentury | Dec 8, 2017
Company News

Astellas acquires build-to-buy Mitobridge

...held the option under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....
BioCentury | Dec 2, 2017
Company News

Astellas acquires build-to-buy Mitobridge

...million in milestones under an amended 2013 deal. Created in 2012 by MPM Capital as Mitokyne Inc....
...The deal is expected to close in the next several weeks. Jaime De Leon MA-0211 MA-0217 MTB-1 MTB-2 Astellas Pharma Inc. Mitobridge Inc. Mitokyne Inc. MPM...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...basic research and creation of drug-like molecules,” he said. Mitobridge was created by MPM as Mitokyne Inc....
BioCentury | Aug 16, 2017
Clinical News

Mitobridge's DMD candidate MA-0211 enters Phase I

...expects to begin a trial in ambulatory DMD patients next year. In 2013, Mitobridge (formerly Mitokyne Inc....
BioCentury | May 28, 2015
Company News

Astellas adds muscle disease, ophthalmology TAs

...Astellas also said it would explore muscle diseases in partnership with Mitobridge Inc. (formerly Mitokyne...
BioCentury | May 18, 2015
Finance

New (Bio)ventures at MPM

...Astellas and MPM participated in a $45 million series A round for Mitobridge Inc. (then Mitokyne Inc....
BioCentury | Oct 18, 2014
Company News

Astellas, CoMentis end AD collaboration

...commercial milestones and royalties (see BioCentury, May 5, 2008) . In 2013, Astellas partnered with MitoKyne Inc....
BioCentury | May 19, 2014
Emerging Company Profile

Mitokyne: Energy pipeline

...mitochondrial activity to treat neuromuscular, cardiovascular and metabolic diseases, starting with Orphan or hereditary indications. Mitokyne...
...and former CEO of Epizyme Inc. Shiosaki is managing partner at MPM Capital, which seeded Mitokyne...
...$45 million series A round last October. Under a deal with Astellas Pharma Inc. , Mitokyne...
BioCentury | Mar 17, 2014
Emerging Company Profile

Partikula: Mitochondrial delivery

...delivering payloads into the mitochondria. Partikula is not the only company focused on mitochondria, however. Mitokyne Inc....
...neurodegenerative disorders as well as aging diseases. Details about Mitokyne's technology are undisclosed. Last year, Mitokyne...
...for up to $730 million. Companies and Institutions Mentioned Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Mitokyne Inc....
BioCentury | Oct 14, 2013
Company News

Mitokyne board of directors update

Mitokyne Inc. , Boston, Mass. Business: Neurology, Endocrine/Metabolic Appointed: Rich Aldrich, partner at Longwood Founders Fund; Ansbert Gadicke, managing director at MPM Capital; and an undisclosed representative from Astellas Pharma Inc. WIR Staff...
Items per page:
1 - 10 of 13